Latest news with #OM1
Business Wire
13-05-2025
- Business
- Business Wire
OM1's PhenOM ® Foundation AI Surpasses One Billion Years of Health History in Model Training
BOSTON--(BUSINESS WIRE)-- OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM ® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date. PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations. 'Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,' said Dr. Richard Gliklich, CEO of OM1. 'PhenOM is not just a model, it's an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.' In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives. OM1's innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1's technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company's position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development. Meet our PhenOM experts and learn more at ISPOR 2025, booth #1500. About OM1: OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
National Post
13-05-2025
- Health
- National Post
OM1's PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training
Article content Article content BOSTON — OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM ® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date. Article content PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations. Article content 'Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,' said Dr. Richard Gliklich, CEO of OM1. 'PhenOM is not just a model, it's an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.' Article content In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives. Article content OM1's innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1's technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company's position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development. Article content OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE. Article content Article content Article content Article content Article content Contacts Article content Article content
Yahoo
08-05-2025
- Health
- Yahoo
OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025
BOSTON, May 08, 2025--(BUSINESS WIRE)--OM1: What:OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1's Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. When:The poster session will be held at ISPOR 2025 on Wednesday, May 14, from 4:00 – 7:00 PM, with a discussion period from 6:00 – 7:00 PM. Key Findings:Amid growing scrutiny of GLP-1 receptor agonists (used in diabetes and obesity), OM1's real-world study finds no significant change in suicidal ideation (SI) following treatment initiation across both therapeutic populations. Why It Matters:GLP-1s indicated for obesity feature a package label warning for suicidal ideation, whereas those indicated for diabetes do not. This research adds to the growing body of evidence exploring whether this warning may present an unnecessary obstacle to treatment and a potential barrier to equitable access to healthcare for a long stigmatized population. Suicidal ideation is often undercoded or missing entirely in claims-based datasets. By applying natural language processing (NLP) to unstructured clinician notes, OM1's study captures a richer, more nuanced view of patient mental health. This study reinforces the role of AI and real-world data (RWD) in advancing pharmacovigilance and public health safety. Implications for Stakeholders: Supports regulatory and labeling evaluations, Facilitates risk-benefit communications, Enables signal detection and mitigation strategies. About OM1:OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE. View source version on Contacts Media Contact: Kristine ChristieVice President, Marketingkchristie@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Health
- Yahoo
OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025
BOSTON, May 08, 2025--(BUSINESS WIRE)--OM1: What:OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1's Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. When:The poster session will be held at ISPOR 2025 on Wednesday, May 14, from 4:00 – 7:00 PM, with a discussion period from 6:00 – 7:00 PM. Key Findings:Amid growing scrutiny of GLP-1 receptor agonists (used in diabetes and obesity), OM1's real-world study finds no significant change in suicidal ideation (SI) following treatment initiation across both therapeutic populations. Why It Matters:GLP-1s indicated for obesity feature a package label warning for suicidal ideation, whereas those indicated for diabetes do not. This research adds to the growing body of evidence exploring whether this warning may present an unnecessary obstacle to treatment and a potential barrier to equitable access to healthcare for a long stigmatized population. Suicidal ideation is often undercoded or missing entirely in claims-based datasets. By applying natural language processing (NLP) to unstructured clinician notes, OM1's study captures a richer, more nuanced view of patient mental health. This study reinforces the role of AI and real-world data (RWD) in advancing pharmacovigilance and public health safety. Implications for Stakeholders: Supports regulatory and labeling evaluations, Facilitates risk-benefit communications, Enables signal detection and mitigation strategies. About OM1:OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE. View source version on Contacts Media Contact: Kristine ChristieVice President, Marketingkchristie@ Sign in to access your portfolio
National Post
08-05-2025
- Health
- National Post
OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025
Article content Article content What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1's Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. Article content When: The poster session will be held at ISPOR 2025 on Wednesday, May 14, from 4:00 – 7:00 PM, with a discussion period from 6:00 – 7:00 PM. Article content Key Findings: Amid growing scrutiny of GLP-1 receptor agonists (used in diabetes and obesity), OM1's real-world study finds no significant change in suicidal ideation (SI) following treatment initiation across both therapeutic populations. Article content Why It Matters: GLP-1s indicated for obesity feature a package label warning for suicidal ideation, whereas those indicated for diabetes do not. This research adds to the growing body of evidence exploring whether this warning may present an unnecessary obstacle to treatment and a potential barrier to equitable access to healthcare for a long stigmatized population. Article content Suicidal ideation is often undercoded or missing entirely in claims-based datasets. By applying natural language processing (NLP) to unstructured clinician notes, OM1's study captures a richer, more nuanced view of patient mental health. This study reinforces the role of AI and real-world data (RWD) in advancing pharmacovigilance and public health safety. Article content About OM1: OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE. Article content Article content Article content Article content Article content Contacts Article content Article content
